The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline

4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline

Discover how PubCompare.ai's innovative AI-powered platform can streamline your research on 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline.
Our tool helps users locate the best protocols from literature, preprints, and patents using AI-driven comparisons to enhance reproducibility and accuracy.
Simplify your workflow with this cutting-edge solution.

Most cited protocols related to «4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline»

The most significant gene from two critical subnetworks was selected for subsequent molecular docking analysis. The receptor protein coded by the selected gene was searched in the Uniprot database (https://www.uniprot.org/). We downloaded 3D structure of the protein in RCSB PDB database (https://www.rcsb.org/). The 2D structure for the molecule ligands was downloaded from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). ChemBio 3D software was used to calculate and export the 3D structure by minimizing energy. PyMOL 2.4.0 software was performed the dehydration of the receptor protein and Autodock software was used to carry out hydrogenation and charge calculation of proteins. Parameters of the receptor protein docking site were set to include the active pocket sites where small molecule ligands bind. Finally, Autodock Vina was used to dock the receptor protein with the small molecule ligands of the active compounds of LQC.32
Full text: Click here
Publication 2020
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Binding Sites Dehydration Genes Hydrogenation Ligands Molecular Structure Proteins Rumex

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2021
1,2-distearoyllecithin 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Amines Biological Assay Buffers Cations Cholesterol Citrates Dialysis Endotoxins Ethanol Lipid A Lipids Molar Nitrogen Parent Phosphates polyethylene glycol 2000 Prodrugs Ribonucleases Rivers RNA, Messenger Steroids

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2016
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Amber Embryo Fertilization Gas Chromatography-Mass Spectrometry n-hexane Polycyclic Hydrocarbons, Aromatic
QSAR models establish quantitative relationships between chemical structures characterized by chemical descriptors and a target property, e.g., biological activity of chemicals in specific biological assays. Validated and externally predictive models29 (link) can be applied to screen virtual chemical libraries to retrieve compounds with desired properties.32 (link), 37 (link), 38 (link) QSAR modeling employs complex machine leaning algorithms such as Support Vector Machines (SVM) or the k Nearest Neighbors (kNN) that take the descriptor matrix of compounds as inputs and output a predicted value for the modeled property.
The QSAR modeling workflow can be divided into three major steps: (i) data preparation/analysis39 (link) (selection of compounds and descriptors), (ii) model building, and (iii) model validation/selection (including the evaluation of its Applicability Domain – AD). A set of compounds with known experimental activity is randomly split into several training and test sets. Models are built using compounds of each training set and then applied to test set compounds to assess their properties. After application of rigorous tests (such as leave one out, n-fold cross-validation, and Y-randomization), and calculation of model accuracy metrics described below, certain models are selected if and only if they can reasonably predict both the training set as assessed by cross-validation procedures and the test set.40 (link) Models obtained for the modeling set with randomized activities (Y-randomization) should have significantly lower predictive capabilities than models built using modeling set with real activities. Finally, the selected models are applied to the external validation set compounds.
Chemical structures are represented by molecular descriptors.41 In Case Study 2, we used the following two-dimensional MOE descriptors (commercial software distributed by Chemical Computing Group): physical properties, surface areas, atom and bond counts, Kier & Hall connectivity indices, kappa shape indices, adjacency and distance matrix descriptors, pharmacophore feature descriptors, and molecular charges.
The clustering of a chemical dataset consists of merging compounds into independent clusters that include chemically similar molecules42 based on any similarity metrics (e.g., compounds can be clustered based on their biological activity profiles). In this study, we have employed the ISIDA/Cluster program31 implementing the Sequential Agglomerative Hierarchical Non-overlapping (SAHN) method. The parent-child relationships between clusters result in a hierarchical data representation, or dendrogram. In particular, we used ISIDA/Cluster to obtain the heat map of the proximity matrix and the dynamic dendrogram (Fig. 2).
The kNN QSAR method43 (link), 44 (link) is based on the idea that the activity of a given compound can be predicted by averaging the activities of k compounds from the modeling set, which are most chemically similar to this compound. Briefly, our algorithm employs the kNN classification principle and variable selection procedure (simulated annealing with the Metropolis-like acceptance criteria): it generates both an optimum k value, typically from one to five, and an optimal nvar subset of descriptors that maximize the QSAR model’s training set accuracy as estimated by the Q2abs statistical parameter. The Euclidean distance between compounds is used as a metric that characterizes compounds’ dissimilarity in multidimensional descriptor space. Additional details of the method can be found elsewhere.29 (link) For SVM classification, we used the WinSVM program (version 1.1.8)37 (link) developed in our group at UNC, which implements the opensource libsvm package (http://www.csie.ntu.edu.tw/~cjlin/libsvm/).
The Applicability Domain (AD) of a model is defined in order to determine if a given model is capable of predicting the activity of a query compound29 (link), 38 (link) within a reasonable error. In this study, we defined the AD as a threshold distance DT between a query compound and its nearest neighbors in the training set, calculated as follows: DT = ȳ + Zσ where ȳ is the average Euclidean distance between each compound and its k nearest neighbors in the training set, σ is the standard deviation of the Euclidean distances, and Z is an arbitrary parameter to control the significance level; k is the parameter optimized in the course of QSAR modeling. We set the default value of Z at 0.5, which formally places the allowed distance threshold at the mean plus one-half of the standard deviation. If the distance of the test compound from any of its k nearest neighbors in the training set exceeds the threshold, the prediction is considered unreliable. In this study, we used this same approach for both Case Studies 1 and 2.
We used different statistical parameters to evaluate the performance of models. For binary classification problems (like Case Study 1), these are defined as: Accuracy = (TP + TN) / (NA + NI); Sensitivity = TP / NA; Specificity = TN / NI; CCR = 0.5 (Sensitivity + Specificity), where NA is the total number of actives (or class 1), NI is the total number of inactives (or class 0), TP is the number of true positives (experimentally actives predicted as actives), TN is the number of true negatives (experimentally inactives predicted as inactives), and CCR is the Correct Classification Rate.
When activities were represented by a range of values (Case Study 2), we used squared correlation coefficient (R2abs) for test set compounds, squared leave-one-out cross-validation correlation coefficient (Q2abs) for training set compounds, and mean absolute error (MAE) for the linear correlation between predicted (Ypred) and experimental (Yexp) data. For this study, Y is the Paca2 cellular uptake. These parameters are defined as follows: Rabs2=1Y(YexpYpred)2/Y(Yexp<Y>exp)2,Qabs2=1Y(YexpYLOO)2/Y(Yexp<Y>exp)2,MAE=Y|YYpred|/n . In Case Study 1, the classification models were considered acceptable if CCRCV ≥ 0.6 and CCRtest ≥ 0.6, whereas the regression models were considered acceptable in Case Study 2 if Q2abs > 0.6 and R2abs > 0.6.
Publication 2010
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline 11-dehydrocorticosterone Biological Assay Biopharmaceuticals Cells Chemical Actions ginsenoside M1 Hypersensitivity Muscle Rigidity Physical Processes
To a solution of 27 (50 mg, 0.18 mmol) in anhydrous THF, were added triethylamine (26 mg, 0.19 mmol) and hexanoyl chloride. The reaction mixture was stirred at room temperature for 6 hours. The solvent was then removed under vacuum, and the residue was dissolved in ethyl acetate and washed with water. The ethyl acetate fraction was dried using Na2SO4 and evaporated under vacuum to obtain the intermediate amide compound. This was dissolved in 0.1 ml of 2M solution of ammonia in MeOH. The sealed reaction vessel was heated in microwave at 150 °C for 1 hour. The solvent was then removed under vacuum and the residue was purified using column chromatography (7% MeOH/dichloromethane) to obtain the compound 32 (8 mg; unoptimized yields). 1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 1H), 7.72 (dd, J = 8.3, 1.0 Hz, 1H), 7.44 (qd, J = 7.0, 3.5 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.18 – 7.10 (m, 1H), 7.06 (d, J = 6.9 Hz, 2H), 5.74 (s, 2H), 5.60 (s, 2H), 2.95 – 2.79 (m, 2H), 1.80 (dt, J = 15.6, 7.6 Hz, 2H), 1.42 – 1.27 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 153.50, 150.28, 134.61, 133.41, 128.61, 127.40, 126.51, 125.94, 125.85, 124.85, 121.69, 119.07, 114.42, 48.20, 30.85, 26.97, 26.77, 21.65, 13.23. MS (ESI) calculated for C22H24N4, m/z 344.20, found 345.21 (M + H)+. 2D 1H COSY and NOESY experiments (included in Supporting Information) provided unambiguous assignment of 1H resonances.
Publication 2010
1H NMR 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Amides Ammonia Blood Vessel Carbon-13 Magnetic Resonance Spectroscopy Chlorides Chromatography ethyl acetate Methylene Chloride Microwaves Solvents triethylamine Vacuum Vibration

Most recents protocols related to «4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline»

Example 32

[Figure (not displayed)]

To a solution of compound 32-1 (650 mg, 1.44 mmol, 1 eq) in EtOH (2 mL) was added H2SO4 (1.20 g, 12.19 mmol, 0.65 mL, 8.47 eq) and sodium nitrite (298.1 mg, 4.32 mmol, 3 eq). The mixture was stirred at 60° C. for 2 hr. The reaction mixture was diluted with H2O (5 mL) and the mixture was extracted with EA (5 mL*3). The combined organic phase was washed with brine (5 mL*3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=0/1 to 1:1) to give the crude product (180 mg, 0.30 mmol, 20.9% yield) as a white solid. 40 mg of the crude product were purified by prep-HPLC to give the title compound (26 mg) as white solid. LCMS (ESI): RT=0.949 min, mass calc. for C21H17BrF3NO 435.04, m/z found 437.7 [M+H]+; 1H NMR (400 MHz, DMSO-d6) δ 1.08-1.29 (m, 1H) 1.21 (d, J=6.53 Hz, 5H) 4.15 (dq, J=13.80, 6.69 Hz, 1H) 7.67-7.79 (m, 1H) 7.71 (d, J=2.01 Hz, 1H) 7.76 (d, J=8.53 Hz, 2H) 7.89-7.99 (m, 3H) 8.39-8.52 (m, 3H).

Full text: Click here
Patent 2024
1H NMR 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline brine Chromatography Ethanol ethyl acetate High-Performance Liquid Chromatographies Lincomycin naphtha naphthalene-2-carboxamide Sodium Nitrite Sulfoxide, Dimethyl Vacuum

Example 32

[Figure (not displayed)]

To a solution of (R)-5-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1,3,4-oxadiazole-2-carboxamide (105 mg, 0.21 mmol) in CH3CN (8 mL) was added 1,1-difluoro-2-iodoethane (23 μL, 0.26 mmol) and potassium carbonate (89 mg, 0.64 mmol). The mixture was stirred at 80° C. for 18 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated and the crude product was purified by prep-HPLC (CH3CN/H2O with 0.05% TFA as mobile phase) to give (R)-5-(tert-butyl)-N-(2-(2,2-difluoroethyl)-8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1,3,4-oxadiazole-2-carboxamide as a yellow solid (30 mg, yield: 25%). ESI-MS (M+H)+: 552.0. 1H NMR (400 MHz, METHANOL-d4) δ: 8.42 (d, J=5.3 Hz, 1H), 8.23 (d, J=8.4 Hz, 1H), 8.19 (s, 1H), 7.95 (s, 1H), 7.68-7.65 (m, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.30 (d, J=5.5 Hz, 1H), 6.40 (tt, J=53.5 Hz, 3.6 Hz, 1H), 5.70 (dd, J=9.8 Hz, 2.5 Hz, 1H), 4.83 (br d, J=14.3 Hz, 1H), 4.67 (br d, J=14.3 Hz, 1H), 3.90 (s, 3H), 3.83-3.67 (m, 2H), 3.59 (dt, J=15.0 Hz, 3.4 Hz, 2H), 2.52-2.31 (m, 2H), 1.49 (s, 9H)

Full text: Click here
Patent 2024
1H NMR 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline High-Performance Liquid Chromatographies iodoethane Methanol Oxadiazoles potassium carbonate pyrazole TERT protein, human

Example 27

[Figure (not displayed)]

An aqueous solution of LiOH (0.4 N, 47.7 mL, 19.1 mmol, 4.0 eq.) was added to a solution of compound 31 (2.50 g, 4.76 mmol, 1.0 eq.) in dioxane (47.7 mL) at 0° C. The reaction mixture was stirred at r.t. for 2 h and then concentrated. Column chromatography (100% CH2Cl2 to CH2Cl2/MeOH/NH4OH 80:20:1) afforded compound 32 (2.36 g, 99% yield) as an amorphous solid. MS ESI m/z calcd for C24H41N4O5S [M+H]+ 497.27, found 497.28.

Full text: Click here
Patent 2024
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Anabolism Chromatography dioxane
Not available on PMC !

Example 11

The kinase selectivity of the compounds of the present application was assessed using the KINOMEscAN™ methodology across a panel of 456 kinases (Ambit Biosciences, San Diego, Calif.). Compounds 6 and 32 were screened at a concentration of 1 μM. Both compounds were slightly less selective than Alectinib. Compound 6 was more selective than compound 32 with 34 interactions mapped compared to 39 with an S-score (1)=0.06, which may explain the increase in cytotoxicity against the neuroblastoma cell lines (FIG. 3). Dose—response analysis using Compound 6 revealed inhibition of CSNK2A1<10 μM, IRAK1 with an IC50=14 nM, IRAK 4 with an IC50=465 nM, CLK4 with an IC50=14 nM, RET with an IC50=3 nM, RET V804L with an IC50=13 nM, and RET V804M with an IC50=12 nM. Dose—response analysis using compound 32 revealed inhibition of CSNK2A1<10 μM, IRAK1 with an IC50=15 nM, IRAK 4 with an IC50=234 nM, CLK4 with an IC50=4 nM, RET with an IC50=2 nM, RET V804L with an IC50=9 nM, and RET V804M with an IC50=23 nM.

Full text: Click here
Patent 2024
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline alectinib Cell Lines CSNK2A1 protein, human Cytotoxin IRAK1 protein, human Neuroblastoma Phosphotransferases Psychological Inhibition

Example 13

To about 3 mL of saturated or cloudy solutions of Compound 1 Di-Hydrochloric Acid Salt Form I prepared in n-butanol was added about 25 mg of Compound 1 Di-Hydrochloric Acid Salt Form I followed by stirring at 25±1° C. for 3 days, which was filtered and analyzed by XRPD as Compound 1 Di-Hydrochloric Acid Salt Form IV.

The crystallinity of the di-hydrochloric acid salt Form IV was confirmed by XRPD (FIG. 17, Table 17) and further supported by DSC (FIG. 18), indicating the salt having an endothermic peak with an onset temperature at 268.1° C. and a maximum at 273.0° C. TGA of the di-hydrochloric acid salt Form IV is provided in FIG. 19, and exhibited approximately 1.2% of weight loss up to about 100° C. The di-hydrochloric acid salt Form IV was further characterized by NMR as an n-butanol channel solvate (FIG. 20).

TABLE 17
XRPD Peak Data for the Compound 1
Di-Hydrochloric Acid Salt Form IV
Relative
2-Thetaintensity %
5.4100.0
8.834.9
10.92.7
13.03.4
15.117.9
16.226.4
17.559.8
21.932.1
26.366.0

Full text: Click here
Patent 2024
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline Butyl Alcohol Hydrochloric acid Salts

Top products related to «4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline»

The MicroTOF II ESI-TOF-MS spectrometer is a high-resolution time-of-flight mass spectrometer equipped with an electrospray ionization (ESI) source. It is designed to perform accurate mass measurements and elemental composition analysis of a wide range of molecules, including small organic compounds, peptides, and proteins.
The Ascend® 850 NMR spectrometer is a high-performance nuclear magnetic resonance (NMR) instrument designed for advanced analytical applications. It features a superconducting magnet that generates a powerful magnetic field, enabling precise and sensitive detection of molecular structures and compositions.
Methyltetrazine-PEG4 succinimidyl ester is a bifunctional linker molecule that can be used to conjugate biomolecules. It contains a methyltetrazine group and an N-hydroxysuccinimide (NHS) ester group, which allows for site-specific labeling of primary amines on proteins or other biomolecules.
Sourced in Germany, United States, Switzerland, Italy, United Kingdom
Topspin 2.1 is a software application designed for nuclear magnetic resonance (NMR) data acquisition, processing, and analysis. It provides a comprehensive suite of tools for managing and interpreting NMR spectra. The software is compatible with a variety of Bruker NMR spectrometers and can be used in a range of scientific applications.
ATCC® VR-64™ is a laboratory product offered by American Type Culture Collection. It is a specific viral strain that can be used for various research and testing purposes. No further details about its core function or intended use are provided to maintain an unbiased and factual approach.
Sourced in Switzerland, Austria, United States, Italy, Germany, Japan, Australia, China
The Infinite M1000 Pro is a multimode microplate reader designed for versatile and precise measurements in life science research and drug discovery applications. It offers a wide range of detection modes, including absorbance, fluorescence, luminescence, and time-resolved fluorescence. The instrument is capable of accurate quantification, kinetic studies, and endpoint analyses across a variety of sample types and microplate formats.
Sourced in Germany
The Ascend 600 NMR spectrometer is a high-performance nuclear magnetic resonance instrument designed for advanced analytical applications. It features a superconducting magnet that generates a strong, stable magnetic field for precise molecular structure analysis.
Sourced in United States, Denmark, Germany, United Kingdom, Switzerland
The Black 96-well plate is a laboratory equipment product designed for various applications in life science research, clinical diagnostics, and drug discovery. It is a polystyrene microplate with 96 individual wells, each with a black-colored interior. The black color helps to reduce light interference, which can be beneficial for certain types of assays, such as fluorescence-based experiments. The 96-well format is a standard in the industry, allowing for efficient and high-throughput sample processing.
DBCO-PEG4 succinimidyl ester is a heterobifunctional crosslinking reagent. It contains a dibenzocyclooctyne (DBCO) group and an N-hydroxysuccinimide (NHS) ester group, which can be used for site-specific conjugation of biomolecules through copper-free click chemistry and amine-reactive coupling, respectively.

More about "4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline"

4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline, also known as BQD, is a chemical compound with applications in various research fields.
It is commonly used as a starting material in the synthesis of pharmaceutical intermediates and can be analyzed using advanced analytical techniques like MeSH-TOF II ESI-TOF-MS spectrometry and Ascend® 850 NMR spectrometry.
Researchers can utilize PubCompare.ai's innovative AI-powered platform to streamline their workflow and enhance the reproducibility and accuracy of their studies on BQD.
The platform helps users locate the best protocols from literature, preprints, and patents using AI-driven comparisons, allowing them to identify the most effective methods and products.
Key subtopics related to BQD include its chemical structure, synthesis, purification, and characterization.
Researchers may also be interested in exploring its biological activities, such as its potential as a therapeutic agent or a chemical probe.
Additionally, the use of related compounds like Methyltetrazine-PEG4 succinimidyl ester, DBCO-PEG4 succinimidyl ester, and ATCC® VR-64™ may be relevant in certain applications.
PubCompare.ai's platform can be particularly useful for researchers working with BQD, as it provides a comprehensive and efficient way to navigate the available protocols and identify the most suitable ones for their specific needs.
By streamlining the research process and enhancing reproducibility, the platform can help researchers save time and resources while improving the quality of their work.